Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이동윤 | - |
dc.date.accessioned | 2021-03-31T00:43:33Z | - |
dc.date.available | 2021-03-31T00:43:33Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.citation | BIOINSPIRED BIOMATERIALS: ADVANCES IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE, v. 1249, page. 203-221 | en_US |
dc.identifier.isbn | 978-981-15-3258-0 | - |
dc.identifier.isbn | 978-981-15-3257-3 | - |
dc.identifier.issn | 0065-2598 | - |
dc.identifier.issn | 2214-8019 | - |
dc.identifier.uri | https://link.springer.com/chapter/10.1007%2F978-981-15-3258-0_13 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/160978 | - |
dc.description.abstract | Despite the use of active surgeries, radiotherapy, and chemotherapy in clinical practice, brain tumors are still a difficult health problem due to their rapid development and poor prognosis. To treat brain tumors, various nanoparticles can be used to target effective physiological conditions based on continuously changing vascular characteristics and microenvironments to promote effective brain tumor-targeting drug delivery. In addition, a brain tumor-targeting drug delivery system that increases drug accumulation in the brain tumor area and reduces toxicity in the normal brain and peripheral tissues is needed. However, the blood-brain barrier is a big obstacle for drug delivery to the brain. In this chapter, we provide a broad overview of brain drug delivery and current strategies over the last few years. In addition, several questions have been reconsidered, such as whether nanoparticles believed to be delivered to the brain can pass through the blood-brain barrier, whether the drug is delivered to the target site, and what brain tumor treatment is possible. | en_US |
dc.description.sponsorship | This study was supported by the Bio & Medical Technology Development Program (NRF-2015M3A9E2030125) and was partially supported by the Creative Materials Discovery Program (NRF-2017M3D1A1039289) through the National Research Foundation (NRF) funded by the Korean government (MSIP & MOHW). Also, this study was partially supported by a grant of the Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0453). | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER-VERLAG SINGAPORE PTE LTD | en_US |
dc.subject | Brain tumor | en_US |
dc.subject | Drug delivery | en_US |
dc.subject | Oral administration of protein-based drug | en_US |
dc.subject | Drug stability | en_US |
dc.title | Protein-based drug delivery in brain tumor therapy | en_US |
dc.type | Article | en_US |
dc.relation.volume | 1249 | - |
dc.identifier.doi | 10.1007/978-981-15-3258-0_13 | - |
dc.relation.page | 203-221 | - |
dc.relation.journal | ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY | - |
dc.contributor.googleauthor | Hwang, Hae Hyun | - |
dc.contributor.googleauthor | Lee, Dong Yun | - |
dc.relation.code | 2020045429 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | dongyunlee | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.